No profile data available.
Nyxoah SA (NYXH) is a healthcare company in the targeted healthcare equipment industry, based in Mont-Saint-Guibert, Belgium, with about 153 full-time employees.
It reported revenue of 4.52 million EUR for fiscal year 2024, up 4.0% from fiscal year 2023, and net income of -59.24 million EUR. Germany was its largest region in fiscal year 2025, with 49% of revenue. Its market capitalization was $138.50 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA reported 4.52 million EUR in revenue for fiscal year 2024, up 4.0% from 4.35 million EUR in fiscal year 2023.
Germany: 49% of revenue by region in fiscal year 2025, followed by UNITED STATES (40%).
$138.50 million as of October 9, 2026.
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Inogen, Inc. (INGN), Neuronetics, Inc. (STIM), Solana Co (HSDT), Humacyte, Inc. (HUMA).